(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 86.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.27%, and while it is forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Sangamo Therapeutics's revenue in 2025 is $32,875,000.On average, 8 Wall Street analysts forecast SGMO's revenue for 2026 to be $14,890,217,633, with the lowest SGMO revenue forecast at $2,835,975,553, and the highest SGMO revenue forecast at $40,278,390,333. On average, 7 Wall Street analysts forecast SGMO's revenue for 2027 to be $44,790,781,431, with the lowest SGMO revenue forecast at $8,573,879,580, and the highest SGMO revenue forecast at $92,428,306,239.
In 2028, SGMO is forecast to generate $71,114,745,305 in revenue, with the lowest revenue forecast at $6,595,291,984 and the highest revenue forecast at $150,160,665,716.